Applications of Eculizumab, a humanized anti-complement factor C5 monoclonal antibody

Abstract

Abstract: The complement system is an important part of the innate immune system. Complement plays a crucial role in the pathophysiology of many disorders. Paroxysmal nocturnal hemoglobinuria (PNH) is a refractory hemolytic disease caused by acquired hematopoietic stem cell gene mutation. Eculizumab is a humanized monoclonal antibody that inhibits complement factor C5. It was approved as the only recognition of directional drug for the treatment of PNH by the US FDA and the European Commission in 2007. In this article, the applications of Eculizumab in treating PNH and other complement related diseases in recent years will be reviewed.

Key words: monoclonal antibody, Eculizumab, paroxysmal nocturnal hemoglobinuria (PNH)

CLC Number:

R552

WANG Yan, LV Li. Applications of Eculizumab, a humanized anti-complement factor C5 monoclonal antibody[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 455-459.

References

[1] Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria[J]. Nat Biotechnol, 2007, 25(11):1256-1264.
[2] Parker CJ. The pathophysiology of paroxysmal nocturnal hemoglobinuria[J]. Exp Hematol, 2007, 35 (4): 523-533.
[3] Bessler M, Hiken J. The pathophysiology of disease in patients with paroxysmal nocturnal hemoglobinuria[J]. Hematology Am Soc Hematol Educ Program, 2008, 2008:104-110.
[4] Savage WJ, Brodsky RA. New insights into paroxysmal nocturnal hemoglobinuria[J]. Hematology, 2007, 12(5): 371-376.
[5] Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria[J]. N Engl J Med, 1995, 333(19):1253-1258.
[6] de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories[J]. Blood, 2008, 112(8):3099-3106.
[7] Hill A, Richards SJ, Hillmen P. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria[J]. Br J Haematol, 2007, 137 (3): 181-192.
[8] Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin[J]. JAMA, 2005, 292 (13): 1653-1662.
[9] Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria[J]. N Engl J Med, 2004, 350(6):552- 559.
[10]Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria[J]. Blood, 2008, 111(4):1840-1847.
[11]Hillmen P, Muus P, Dührsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria[J]. Blood, 2007, 110(12):4123-4128.
[12] Höchsmann B, Leichtle R, von Zabern I, et al. Paroxysmal nocturnal hemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test[J]. Vox Sang, 2012,102(2):159-166.
[13]Risitano AM, Notaro R, Luzzatto L, et al. Paroxysmal nocturnal hemoglobinuria - hemolysis before and after eculizumab[J]. N Engl J Med, 2010, 363(23):2270-2272.
[14]Kristiansen M, Graversen JH, Jacobsen C, et al. Identification of the haemoglobin scavenger receptor[J]. Nature, 2001, 409(6817):198-201.
[15]Olson JS, Foley EW, Rogge C, et al. NO scavenging and the hypertensive effect of hemoglobin-based blood substitutes[J]. Free Radic Biol Med, 2004, 36(6):685-697.
[16]Hill A, Rother RP, Wang X, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria[J]. Br J Haematol, 2010, 149(3):414-425.
[17]Schafer A, Wiesmann F, Neubauer S, et al. Rapid regulation of platelet activation in vivo by nitric oxide[J]. Circulation, 2004, 109(15):1819-1822.
[18]Matejovic M, Krouzecky A, Radej J, et al. Coagulation and endothelial dysfunction during longterm hyperdynamic porcine bacteremia - effects of selective inducible nitric oxide synthase inhibition[J]. Thromb Haemost, 2007, 97(2):304-309.
[19]Gralnick HR, Vail M, McKeown LP, et al. Activated platelets in paroxysmal nocturnal haemoglobinuria[J]. Br J Haematol, 1995, 91(3):697-702.
[20]Hugel B, Socie G, Vu T, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia[J]. Blood, 1999, 93(10):3451-3456.
[121]Helley D, de Latour RP, Porcher R, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab[J]. Haematologica, 2010, 95(4):574-581.
[22]Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival[J]. Blood, 2011, 117(25):6786-6792.
[23]Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria[J]. Am J Hematol, 2010, 85(8):553-559.
[24]Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan[J]. Medicine (Baltimore), 2004, 83(3):193-207.
[25]Scheinberg P,Marte M,Nunez 0,et a1.Paroxysmal nocturnal hemoglobinuria clones in severe Aplastic anemia patients treated with horse antithymoeyte globulin plus cyclosporine[J]. Haematologiea,2010,95:1075-1080.
[26]Parker CJ.The pathophysiology of paroxysmal nocturnal hemoglobinuria[J].Exp Hematol,2007,35(4):523-533.
[27]Brodsky RA, Young NS, Antonioli E, et a1. Muhicenter phase 3 study of the complement inhibitor eculizumab for the treatnlent of patients with paroxysmal nocturnal henmglobinuria[J]. Blood, 2008, 111(1):1840-l847.
[128]Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria[J]. Nat Biotechnol, 2007, 25 (11): 1256-1264.
[29]Davis J.Eculizumab[J].Am J Health Syst Pharm,2008,65(17):1609-1615.
[30]Schrezenmeier H, Höchsmann B. Drugs that inhibit complement[J]. Transfus Apher Sci, 2012, 46 (1):87-92.
[31]Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome[J]. N Engl J Med , 2009, 361(17):1676-1687.
[32]Kose O, Zimmerhackl LB, Jungraithmayr T, et al. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab[J]. Semin Thromb Hemost, 2010, 36(6):669-672.
[33]Lapeyraque AL, Fremeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome[J]. Pediatr Nephrol, 2011, 26(4):621-624.
[34]Kupferschmidt K. Infectious diseases. As E. coli outbreak recedes, new questions come to the fore[J]. Science, 2011, 333(6038):27.
[35]Biglarnia AR, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation[J]. Transpl Int, 2011, 24(8):e61-e66.
[36]Chandran S, Baxter-Lowe L, Olson JL, et al. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation - a case report[J]. Transplant Proc, 2011, 43(5):2097-2101.
[37]Bommer M, Höchsmann B, Flegel W, et al. Successful treatment of complement mediated refractory hemolysis associated with cold and warm autoantibodies using eculizumab[J]. Haematologica, 2011, 94(Suppl. 2):241[abs. 0593].
[38]Fitzpatrick AM, Mann CA, Barry S, et al. An open label clinical trial of complement inhibition in multifocal motor neuropathy[J]. J Peripher Nerv Syst, 2011, 16(2):84-91.